DBV Technologies S.A. (NASDAQ:DBVT) Receives $48.50 Average PT from Brokerages

Posted by on Sep 2nd, 2026

DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $48.50.

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Finally, Citizens Jmp increased their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th.

Read Our Latest Research Report on DBVT

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new stake in DBV Technologies in the first quarter worth about $20,146,000. Vivo Capital LLC boosted its position in shares of DBV Technologies by 8.4% during the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after purchasing an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of DBV Technologies during the 1st quarter valued at about $21,159,000. Royal Bank of Canada grew its stake in shares of DBV Technologies by 167.1% in the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after purchasing an additional 2,928 shares during the last quarter. Finally, Elmind Capital LP acquired a new position in shares of DBV Technologies in the 1st quarter worth approximately $5,536,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Stock Down 2.9%

Shares of DBVT opened at $13.42 on Wednesday. The firm has a 50-day moving average price of $14.72 and a 200 day moving average price of $18.00. The firm has a market capitalization of $843.78 million, a PE ratio of -3.82 and a beta of -0.93. DBV Technologies has a 52-week low of $8.70 and a 52-week high of $26.18.

About DBV Technologies

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

Featured Stories

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.